ArticleMolecular biomedicine2026

The type I FLT3 inhibitor XL999 overrides secondary FLT3-ITD mutations that arise under gilteritinib and quizartinib treatment in acute myeloid leukemia.

Shiyang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.